ID   SKG-IIIa
AC   CVCL_1704
SY   SKG-IIIA; SKG IIIa; SKGIIIA; SKG-3a; SKG3A; SKG3a
DR   CLO; CLO_0050923
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN01821739
DR   BioSample; SAMN03470894
DR   BioSample; SAMN03471660
DR   cancercelllines; CVCL_1704
DR   Cell_Model_Passport; SIDM00381
DR   ChEMBL-Cells; CHEMBL3308786
DR   ChEMBL-Targets; CHEMBL1075581
DR   Cosmic; 877461
DR   Cosmic; 930298
DR   Cosmic; 1152539
DR   Cosmic; 1995630
DR   Cosmic-CLP; 930298
DR   DepMap; ACH-002020
DR   EGA; EGAS00001000978
DR   GDSC; 930298
DR   GEO; GSM1670429
DR   IARC_TP53; 27576
DR   JCRB; IFO50310
DR   JCRB; JCRB0232
DR   LINCS_LDP; LCL-1804
DR   PharmacoDB; SKGIIIa_1417_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1704
DR   RCB; RCB1892
DR   TKG; TKG 0462
DR   Wikidata; Q54954734
RX   CelloPub=CLPUB00481;
RX   PubMed=6600963;
RX   PubMed=6699456;
RX   PubMed=8380785;
RX   PubMed=9290701;
RX   PubMed=15099960;
RX   PubMed=20164919;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35692560;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>C); ClinVar=VCV000376624; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.18%; Native American=0%; East Asian, North=84.88%; East Asian, South=14.94%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): Cosmic-CLP; JCRB; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 9,11
ST   D18S51: 16
ST   D19S433: 13
ST   D21S11: 31.2,32.2
ST   D2S1338: 19,26
ST   D3S1358: 16
ST   D5S818: 10,11
ST   D7S820: 10 (JCRB)
ST   D7S820: 10,12 (Cosmic-CLP; PubMed=25877200; RCB; TKG)
ST   D8S1179: 11,15
ST   FGA: 21,22
ST   Penta D: 9
ST   Penta E: 10
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C27676; Human papillomavirus-related cervical squamous cell carcinoma
DI   ORDO; Orphanet_213767; Squamous cell carcinoma of the cervix uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2795 ! SKG-IIIb
SX   Female
AG   38Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   CelloPub=CLPUB00481;
RA   Kuno H., Yoshida T.;
RT   "Detection of human papillomavirus types 16, 18, and 33 in cell lines
RT   derived from human genital organs by polymerase chain reaction.";
RL   Res. Commun. Inst. Ferment. Osaka 18:6-12(1997).
//
RX   PubMed=6600963;
RA   Nozawa S., Udagawa Y., Ohta H., Kurihara S., Fishman W.H.;
RT   "Newly established uterine cervical cancer cell line (SKG-III) with
RT   Regan isoenzyme, human chorionic gonadotropin beta-subunit, and
RT   pregnancy-specific beta 1-glycoprotein phenotypes.";
RL   Cancer Res. 43:1748-1760(1983).
//
RX   PubMed=6699456;
RA   Udagawa Y., Nozawa S., Tsukazaki K., Ohta H., Akiba T., Kurihara S.;
RT   "Biological properties of two newly established cell lines (SKG-3a,3b)
RT   from a human uterine cervical epidermoid carcinoma.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 36:237-246(1984).
//
RX   PubMed=8380785; DOI=10.1006/gyno.1993.1016;
RA   Iwasaka T., Oh-uchida M., Matsuo N., Yokoyama M., Fukuda K., Hara K.,
RA   Fukuyama K., Hori K., Sugimori H.;
RT   "Correlation between HPV positivity and state of the p53 gene in
RT   cervical carcinoma cell lines.";
RL   Gynecol. Oncol. 48:104-109(1993).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=15099960; DOI=10.1016/j.ygyno.2004.02.012;
RA   Fujimoto T., Nishikawa A., Iwasaki M., Akutagawa N., Teramoto M.,
RA   Kudo R.;
RT   "Gene expression profiling in two morphologically different uterine
RT   cervical carcinoma cell lines derived from a single donor using a
RT   human cancer cDNA array.";
RL   Gynecol. Oncol. 93:446-453(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35692560; DOI=10.1080/23723556.2022.2078628;
RA   de Lourdes Zuniga-Martinez M., Lopez-Mendoza C.M., Tenorio-Salazar J.,
RA   Garcia-Carranca A.M., Cerbon-Cervantes M.A., Alcantara-Quintana L.E.;
RT   "Establishment, authenticity, and characterization of cervical cancer
RT   cell lines.";
RL   Mol. Cell. Oncol. 9:2078628.1-2078628.10(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//